Abdul Khalifeh

Contributor

tags:   Antibiotic resistance     Big Data     Biologics     Biopharma news     Blockchain     COVID-19     CROs     Healthcare     Pharmaceutical industry trends     R&D Outsourcing     Upcoming Events     Natural Products     Pharma 4.0 (Digital Tech and Data Analytics)     Pharma R&D Outsourcing    

Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.

Posts by this author

WuXi STA to Purchase Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland

   134
WuXi STA to Purchase Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland

Bristol Myers Squibb and WuXi STA – a subsidiary of WuXi AppTec – today announced that WuXi STA has agreed to purchase Bristol Myers Squibb’s manufacturing facility in Couvet, Switzerland.

The Couvet site will be the first facility in Europe for WuXi STA, a leading Contract Development and Manufacturing Organization. The acquisition will enhance WuXi STA’s existing capabilities while growing capacity to support its partners’ life-saving work.
 

WuXi STA’s Integrated CMC Platform Supports InnoCare Orelabrutinib Approved by NMPA

   138
WuXi STA’s Integrated CMC Platform Supports InnoCare Orelabrutinib Approved by NMPA

STA Pharmaceutical, a WuXi AppTec Company (WuXi STA), announces their partner Innocare has received approval by the National Medical Products Administration of China (NMPA) for Orelabrutinib. Under the Marketing Authorization Holder (MAH) policy, WuXi STA provided an integrated and end-to-end support including drug substance, amorphous solid dispersion, tablet and packaging for this product.  Just a couple months ago, with four WuXi STA’s sites inspected at the same time, WuXi STA successfully passed the pre-approval inspection (PAI) for Orelabrutinib from NMPA.